Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab mechanism of action in plaque psoriasis
NCT00115076Phase 3Completed
- Sponsor
- The Rockefeller University
- Start
- Aug 2003
- Primary completion
- May 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of efalizumab in plaque psoriasis, sponsored by The Rockefeller University. Started Aug 2003; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00115076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115076.